Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
BACKGROUND: Using a retrospective cohort study design, we aimed to evaluate the effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who were highly vulnerable.
METHODS: The impact of each drug was determined via comparisons with age-matched control groups of patients positive for SARS-CoV-2 who did not receive oral antiviral therapy.
RESULTS: Administration of molnupiravir significantly reduced the risk of hospitalization (odds ratio [OR], 0.40; P < .001) and death (OR, 0.31; P < .001) among these patients based on data adjusted for age, previous SARS-CoV-2 infection, vaccination status, and time elapsed since the most recent vaccination. The reductions in risk were most profound among elderly patients (≥75 years old) and among those with high levels of drug adherence. Administration of nirmatrelvir/ritonavir also resulted in significant reductions in the risk of hospitalization (OR, 0.31; P < .001) and death (OR, 0.28; P < .001). Similar to molnupiravir, the impact of nirmatrelvir/ritonavir was more substantial among elderly patients and in those with high levels of drug adherence.
CONCLUSIONS: Collectively, these real-world findings suggest that although the risks of hospitalization and death due to COVID-19 have been reduced, antivirals can provide additional benefits to members of highly vulnerable patient populations.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:228 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 228(2023), 12 vom: 20. Dez., Seite 1667-1674 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Paraskevis, Dimitrios [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7R9A5P7H32 |
|---|
| Anmerkungen: |
Date Completed 22.12.2023 Date Revised 20.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiad324 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360650538 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360650538 | ||
| 003 | DE-627 | ||
| 005 | 20240421231933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiad324 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1382.xml |
| 035 | |a (DE-627)NLM360650538 | ||
| 035 | |a (NLM)37565522 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Paraskevis, Dimitrios |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2023 | ||
| 500 | |a Date Revised 20.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: Using a retrospective cohort study design, we aimed to evaluate the effectiveness of molnupiravir and nirmatrelvir/ritonavir in patients with SARS-CoV-2 who were highly vulnerable | ||
| 520 | |a METHODS: The impact of each drug was determined via comparisons with age-matched control groups of patients positive for SARS-CoV-2 who did not receive oral antiviral therapy | ||
| 520 | |a RESULTS: Administration of molnupiravir significantly reduced the risk of hospitalization (odds ratio [OR], 0.40; P < .001) and death (OR, 0.31; P < .001) among these patients based on data adjusted for age, previous SARS-CoV-2 infection, vaccination status, and time elapsed since the most recent vaccination. The reductions in risk were most profound among elderly patients (≥75 years old) and among those with high levels of drug adherence. Administration of nirmatrelvir/ritonavir also resulted in significant reductions in the risk of hospitalization (OR, 0.31; P < .001) and death (OR, 0.28; P < .001). Similar to molnupiravir, the impact of nirmatrelvir/ritonavir was more substantial among elderly patients and in those with high levels of drug adherence | ||
| 520 | |a CONCLUSIONS: Collectively, these real-world findings suggest that although the risks of hospitalization and death due to COVID-19 have been reduced, antivirals can provide additional benefits to members of highly vulnerable patient populations | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antivirals | |
| 650 | 4 | |a molnupiravir | |
| 650 | 4 | |a nirmatrelvir/ritonavir | |
| 650 | 7 | |a nirmatrelvir |2 NLM | |
| 650 | 7 | |a 7R9A5P7H32 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a molnupiravir |2 NLM | |
| 650 | 7 | |a YA84KI1VEW |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Gkova, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Mellou, Kassiani |e verfasserin |4 aut | |
| 700 | 1 | |a Gerolymatos, Gerasimos |e verfasserin |4 aut | |
| 700 | 1 | |a Psalida, Naya |e verfasserin |4 aut | |
| 700 | 1 | |a Gkolfinopoulou, Kassiani |e verfasserin |4 aut | |
| 700 | 1 | |a Kostaki, Evangelia-Georgia |e verfasserin |4 aut | |
| 700 | 1 | |a Loukides, Stylianos |e verfasserin |4 aut | |
| 700 | 1 | |a Kotanidou, Anastasia |e verfasserin |4 aut | |
| 700 | 1 | |a Skoutelis, Athanasios |e verfasserin |4 aut | |
| 700 | 1 | |a Thiraios, Eleftherios |e verfasserin |4 aut | |
| 700 | 1 | |a Saroglou, Georgios |e verfasserin |4 aut | |
| 700 | 1 | |a Zografopoulos, Dimitrios |e verfasserin |4 aut | |
| 700 | 1 | |a Filippou, Dimitrios |e verfasserin |4 aut | |
| 700 | 1 | |a Mossialos, Elias |e verfasserin |4 aut | |
| 700 | 1 | |a Zaoutis, Theoklis |e verfasserin |4 aut | |
| 700 | 1 | |a Gaga, Mina |e verfasserin |4 aut | |
| 700 | 1 | |a Tsiodras, Sotirios |e verfasserin |4 aut | |
| 700 | 1 | |a Antoniadou, Anastasia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 228(2023), 12 vom: 20. Dez., Seite 1667-1674 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:228 |g year:2023 |g number:12 |g day:20 |g month:12 |g pages:1667-1674 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiad324 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 228 |j 2023 |e 12 |b 20 |c 12 |h 1667-1674 | ||